Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA270375
Max Phase: Preclinical
Molecular Formula: C15H27F3OS
Molecular Weight: 312.44
Molecule Type: Small molecule
Associated Items:
ID: ALA270375
Max Phase: Preclinical
Molecular Formula: C15H27F3OS
Molecular Weight: 312.44
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCCCCCCCCCCSCC(=O)C(F)(F)F
Standard InChI: InChI=1S/C15H27F3OS/c1-2-3-4-5-6-7-8-9-10-11-12-20-13-14(19)15(16,17)18/h2-13H2,1H3
Standard InChI Key: NACMLRDTSWENRZ-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 312.44 | Molecular Weight (Monoisotopic): 312.1735 | AlogP: 5.77 | #Rotatable Bonds: 13 |
Polar Surface Area: 17.07 | Molecular Species: NEUTRAL | HBA: 2 | HBD: 0 |
#RO5 Violations: 1 | HBA (Lipinski): 1 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 9.86 | CX Basic pKa: | CX LogP: 6.63 | CX LogD: 6.63 |
Aromatic Rings: 0 | Heavy Atoms: 20 | QED Weighted: 0.40 | Np Likeness Score: -0.48 |
1. Wheelock CE, Nishi K, Ying A, Jones PD, Colvin ME, Olmstead MM, Hammock BD.. (2008) Influence of sulfur oxidation state and steric bulk upon trifluoromethyl ketone (TFK) binding kinetics to carboxylesterases and fatty acid amide hydrolase (FAAH)., 16 (4): [PMID:18023188] [10.1016/j.bmc.2007.10.081] |
2. Harada T, Nakagawa Y, Wadkins RM, Potter PM, Wheelock CE.. (2009) Comparison of benzil and trifluoromethyl ketone (TFK)-mediated carboxylesterase inhibition using classical and 3D-quantitative structure-activity relationship analysis., 17 (1): [PMID:19062296] [10.1016/j.bmc.2008.11.008] |
3. Wheelock CE, Severson TF, Hammock BD.. (2001) Synthesis of new carboxylesterase inhibitors and evaluation of potency and water solubility., 14 (12): [PMID:11743738] [10.1021/tx015508+] |
4. Wheelock CE, Nakagawa Y, Akamatsu M, Hammock BD.. (2003) Use of classical and 3-D QSAR to examine the hydration state of juvenile hormone esterase inhibitors., 11 (23): [PMID:14604674] [10.1016/j.bmc.2003.08.023] |
5. Mouchlis VD, Morisseau C, Hammock BD, Li S, McCammon JA, Dennis EA.. (2016) Computer-aided drug design guided by hydrogen/deuterium exchange mass spectrometry: A powerful combination for the development of potent and selective inhibitors of Group VIA calcium-independent phospholipase A2., 24 (20): [PMID:27320659] [10.1016/j.bmc.2016.05.009] |
Source(1):